Literature DB >> 9657763

Lack of clinically significant contact system activation during platelet concentrate filtration by leukocyte removal filters.

C F Scott1, H Brandwein, J Whitbread, R W Colman.   

Abstract

When blood (plasma) contacts certain foreign surfaces, factor XII can activate and trigger a series of reactions leading to cleavage of kininogens with subsequent release of bradykinin. In this study, we investigated two different widely used leukocyte removal filters, Pall PXL8K (A) and Asahi PLS-5A (B), to test whether clinically significant contact activation occurred during leukodepletion of platelet-rich plasma (PRP). Kininogens were measured by particle concentration fluorescence immunoassay (PCFIA), which can detect cleavage of high and low molecular weight kininogens (HK and LK), the parent molecules of bradykinin, to determine if contact activation had occurred. A slight, nonsignificant decrease in HK and LK was observed with filter A after the first 5 mL was filtered that returned to prefiltration levels by the end of the filtration. Specific TotK (the combined measurement of HK and LK heavy chains divided by plasma protein concentration) showed a small, significant decrease with filter A after the first 5 mL of platelet concentrates was filtered that returned to prefiltration levels by the end of the filtration. There were no significant increases or decreases in the cleaved kininogen index (CKI), an index of HK proteolytic activation or HK and LK destruction (with release of bradykinin). These data suggest that small amounts of both HK and LK initially adsorb to filter A and then desorb, primarily intact. These data also indicate that no significant contact activation, as measured by PCFIA, occurs during leukodepletion of platelet concentrates with either filter A or B.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657763

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  1 in total

1.  Fibrinogen-derived fibrinostatin inhibits tumor growth through anti-angiogenesis.

Authors:  Chuanke Zhao; Yahui Su; Jianzhi Zhang; Qin Feng; Like Qu; Lixin Wang; Caiyun Liu; Beihai Jiang; Lin Meng; Chengchao Shou
Journal:  Cancer Sci       Date:  2015-10-16       Impact factor: 6.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.